Immobilization of human myeloperoxidase on silica gel for inhibitors assessment
Related Experiment Video
Updated: Jun 26, 2026
Hydrophobic Salt-modified Nafion for Enzyme Immobilization and Stabilization
Published on: July 11, 2012
Yalda Cobra Parsajoo1, Cédric Delporte1, Karim Zouaoui Boudjeltia2
1RD3- Pharmacognosy, Bioanalysis and Drug Discovery, Faculty of Pharmacy, Universite Libre de Bruxelles, Boulevard du Triomphe, Campus Plaine CP 205/5, Brussels 1050, Belgium; Analytical Platform of the Faculty of Pharmacy, Universite Libre de Bruxelles, Boulevard du Triomphe, Campus Plaine CP 205/5, Brussels 1050, Belgium.
Abstract:
Myeloperoxidase (MPO), a hemo-protein present in neutrophils and monocytes, significantly contributes to immune responses against microbial pathogens. Increased MPO activity, however, promotes the production of highly reactive oxidized species in extracellular fluids that can damage host tissues causing inflammatory events. To explore the potential of MPO as a target for inhibitor screening, this study aimed to develop and evaluate a mini-reactor system based on immobilized MPO. Several immobilization strategies including physical adsorption and covalent binding, were tested using silica gel as the support material. Among them, immobilization via cyanogen bromide (CNBr) activation was selected as the optimal method based on long-term stability (> 90 % after 20 runs) and a relative activity of 60 % after immobilization. Kinetic parameters for H2O2 were determined to characterize the enzymatic behavior post-immobilization, including Kmapp and Vmax (46 ± 4 µM and 463 ± 38 µM/min, respectively). The system was then employed to evaluate the inhibitory potency (IC₅₀) of three model compounds-salicylhydroxamic acid (SHA), paroxetine (PARO), and 4-aminobenzohydrazide (4-ABAH)-on HOCl production in the presence of 10 µM H₂O₂. 4-ABAH emerged as the most potent irreversible inhibitor (IC₅₀ = 0.30 µM), while SHA was the least effective (IC₅₀ = 27.10 µM). Those results demonstrated that immobilized-MPO preserved its activity and exhibited good stability. This mini-reactor provides a reliable platform for inhibitor studies, offering potential applications in screening therapeutic compounds to mitigate MPO-related inflammatory conditions.
Insights
This study developed a stable immobilized myeloperoxidase (MPO) mini-reactor for screening anti-inflammatory drugs. The system effectively evaluated inhibitor potency, identifying 4-aminobenzohydrazide as a strong MPO inhibitor.
Area of Science:
- Biochemistry
- Enzyme Engineering
- Pharmacology
Background:
- Myeloperoxidase (MPO) is crucial for immunity but can cause inflammation when overactive.
- Developing targeted inhibitors for MPO is vital for treating inflammatory diseases.
- Existing methods for MPO inhibitor screening require optimization for efficiency and stability.
Purpose of the Study:
- To create and validate a robust mini-reactor system using immobilized MPO.
- To assess the stability and activity of immobilized MPO.
- To evaluate the inhibitory potential of compounds against MPO-driven HOCl production.
Main Methods:
- Immobilization of MPO onto silica gel using cyanogen bromide (CNBr) activation.
- Characterization of immobilized MPO's kinetic parameters (Kmapp, Vmax).
- Inhibition assays using model compounds (SHA, PARO, 4-ABAH) to determine IC50 values.
Main Results:
- CNBr activation yielded a stable immobilized MPO with >90% activity after 20 runs.
- Immobilized MPO retained 60% relative activity and showed characteristic kinetics.
- 4-Aminobenzohydrazide (4-ABAH) was the most potent inhibitor (IC50 = 0.30 µM), while SHA was least potent (IC50 = 27.10 µM).
Conclusions:
- The developed immobilized MPO mini-reactor is stable and retains enzymatic activity.
- This system offers a reliable platform for high-throughput screening of MPO inhibitors.
- The findings support the potential of targeting MPO to develop new anti-inflammatory therapeutics.
